SOHO Plenary Lectures: Enduring Medical Education

Estimated Time
1.25 hrs

Release Date
Oct 07, 2024

Expiration Date
Oct 06, 2025

This educational activity is derived from three Plenary Sessions held at the twelfth annual meeting of the Society of Hematologic Oncology (SOHO 2024), originally presented on September 4-7, 2024.

Speakers

Accreditation and Disclosure Information

Target Audience
This CE activity is directed towards physicians, fellows, nurses, physician associates, pharmacists, and students interested in Hematology Oncology, Medical Oncology and Internal Medicine.

Agenda

  • Enhancing Precision Treatment for Childhood Acute Lymphoblastic Leukemia | Ching-Hon Pui, MD, St. Jude Children's Research Hospital, Memphis, TN, USA
  • BCL2 Inhibition in CLL: From Undruggable Target to Standard of Care | John Seymour, MBBS, FRACP, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia
  • Myelodysplastic Neoplasms and the Challenge of Therapeutic Targets: Genetics, Epigenetics, or Inflammation? | Valeria Santini, MD, University of Florence, Florence, Italy

Educational Objectives
After completing this activity, the participant should be better able to:

  • Apply recent national guidelines to guide individualized treatment selection for various blood cancers, focusing on the integration of the latest clinical safety and efficacy data.
  • Differentiate between the advantages and disadvantages of various treatment modalities, including frontline and second-line treatments, CAR T and bispecific therapies, JAK inhibitors, and TKIs, considering individual patient characteristics and needs.
  • Optimize patient assessment by incorporating genetic, biomarker testing, frailty assessments, and consideration of individual characteristics, to ensure effective, individualized patient care.

Jointly provided by:

 

Accreditation and Credit Statements
Joint Accreditation with Commendation LogoIn support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc., and The Society of Hematologic Oncology. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

ECMEC® Credit
ECMEC LogoThe European Union of Medical Specialists-European Accreditation Council for Continuing Medical Education (UEMS-EACCME®) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)™. into European CME credit (ECMEC®) should contact the UEMS (www.uems.eu).

PA
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until October 6, 2025. PAs should only claim credit commensurate with the extent of their participation.

Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-9999-24-083-H01-P
Type of Activity: Knowledge

Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.25 contact hours.

Support Statement
There is no commercial support associated with this activity.

Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc. and The Society of Hematologic Oncology are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures
Presenter
Ching-Hon Pui, MD

Chair, Department of Oncology
St. Jude Children's Research Hospital
Memphis, TN, USA

Ching-Hon Pui, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: Adaptive Biotech, Amgen, Novartis

Presenter
Valeria Santini, MD

Associate Professor of Hematology
University of Florence
Florence, Italy

Valeria Santini, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, Bristol Myers Squibb, CTI, Curis, Geron, Gilead, Keros, Menarini, Novartis, Servier, Syros
Speakers' Bureau: Bristol Myers Squibb

Presenter
John Seymour, MBBS, FRACP, PhD

Director, Cancer Medicine
Director, Department of Haematology
Peter MacCallum Cancer Centre
Melbourne, Australia

John Seymour, MBBS, FRACP, PhD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Genor Bio, Gilead, Janssen, Roche
Research Grant: AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Roche
Speakers' Bureau: AbbVie, AstraZeneca, Bristol Myers Squibb, Roche
Independent Contractor: Genor Biopharma

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and The Society of Hematologic Oncology, the joint provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.

For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board. If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.

For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.

For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/

About This Activity
Medical Learning Institute, Inc. and The Society of Hematologic Oncology are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc. and The Society of Hematologic Oncology.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.

Copyright © 2024 Medical Learning Institute, Inc | All Rights Reserved